Comprehensive Analysis of the Chemokine/Cytokine Profiles in Advanced Mycosis Fungoides and Atopic Dermatitis Article Swipe

PDF

Manami Takahashi , Taku Fujimura , Emi Yamazaki , Ryo Amagai , Kenta Oka , Yumi Kambayashi , Maki Ozawa , Tomoko Chiba , Mayuko Onodera-Amagai , Toshiya Takahashi , Yoshihide Asano ·

YOU? · · 2025 · Open Access · · DOI: https://doi.org/10.1155/dth/6603966

Mycosis fungoides (MF) is an indolent form of cutaneous T‐cell lymphoma. Its early lesions are important to be distinguished from atopic dermatitis (AD) because of their similar immune microenvironment. We have previously demonstrated that several chemokines are involved in the pathogenesis of advanced MF. Therefore, we sought to comprehensively analyze the changes in the immune environment during the advanced phase of MF by focusing on serum cytokines and chemokines and to identify potential biomarkers for the early detection of the transition to the advanced phase of MF. Sera from 11 cases of advanced‐stage MF, 16 cases of mild AD (median EASI score = 5.75), 16 cases of severe AD (median EASI score = 28.1), and 21 healthy volunteers were analyzed using the Bio‐Plex 40 multiplex immunoassay system. The results revealed significant increases in immunosuppressive macrophage‐related factors (IL‐4, MIF, CCL3) in MF patients compared to those with AD and healthy controls. In contrast, IL‐2, CCL1, CCL7, CCL21, CCL25, and CCL26 were significantly increased in severe AD patients compared to MF patients and healthy controls. Our findings suggest that several chemokines and cytokines contribute to an immunosuppressive environment favorable for tumor growth, distinguishing MF from AD. Moreover, T‐cell proliferation and migration factors, which are mainly involved in maintaining inflammation, are elevated in severe AD compared to MF. In addition to elucidating the differences in the pathogenesis of these diseases, these factors may be important in the differential diagnosis of early MF and AD. Further studies are warranted to confirm these findings.

Related Topics

Concepts

Medicine Mycosis fungoides Atopic dermatitis Dermatology Immunology Lymphoma

Metadata

Type: article
Language: en
Landing Page: https://doi.org/10.1155/dth/6603966
PDF: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/dth/6603966
OA Status: hybrid
Cited By: 1
References: 25
Related Works: 10
OpenAlex ID: https://openalex.org/W4410058093

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4410058093

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1155/dth/6603966

Digital Object Identifier
Title: Comprehensive Analysis of the Chemokine/Cytokine Profiles in Advanced Mycosis Fungoides and Atopic Dermatitis

Work title
Type: article

OpenAlex work type
Language: en

Primary language
Publication year: 2025

Year of publication
Publication date: 2025-01-01

Full publication date if available
Authors: Manami Takahashi, Taku Fujimura, Emi Yamazaki, Ryo Amagai, Kenta Oka, Yumi Kambayashi, Maki Ozawa, Tomoko Chiba, Mayuko Onodera-Amagai, Toshiya Takahashi, Yoshihide Asano

List of authors in order
Landing page: https://doi.org/10.1155/dth/6603966

Publisher landing page
PDF URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/dth/6603966

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: hybrid

Open access status per OpenAlex
OA URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/dth/6603966

Direct OA link when available
Concepts: Medicine, Mycosis fungoides, Atopic dermatitis, Dermatology, Immunology, Lymphoma

Top concepts (fields/topics) attached by OpenAlex
Cited by: 1

Total citation count in OpenAlex
Citations by year (recent): 2025: 1

Per-year citation counts (last 5 years)
References (count): 25

Number of works referenced by this work
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4410058093
doi	https://doi.org/10.1155/dth/6603966
ids.doi	https://doi.org/10.1155/dth/6603966
ids.openalex	https://openalex.org/W4410058093
fwci	8.71740399
type	article
title	Comprehensive Analysis of the Chemokine/Cytokine Profiles in Advanced Mycosis Fungoides and Atopic Dermatitis
awards[0].id	https://openalex.org/G5507442718
awards[0].funder_id	https://openalex.org/F4320311405
awards[0].display_name
awards[0].funder_award_id	JP23ym0126041
awards[0].funder_display_name	Japan Agency for Medical Research and Development
awards[1].id	https://openalex.org/G2482676526
awards[1].funder_id	https://openalex.org/F4320334764
awards[1].display_name
awards[1].funder_award_id	23K19525
awards[1].funder_display_name	Japan Society for the Promotion of Science
biblio.issue	1
biblio.volume	2025
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T11811
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9976000189781189
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2708
topics[0].subfield.display_name	Dermatology
topics[0].display_name	Cutaneous lymphoproliferative disorders research
topics[1].id	https://openalex.org/T12856
topics[1].field.id	https://openalex.org/fields/13
topics[1].field.display_name	Biochemistry, Genetics and Molecular Biology
topics[1].score	0.9944000244140625
topics[1].domain.id	https://openalex.org/domains/1
topics[1].domain.display_name	Life Sciences
topics[1].subfield.id	https://openalex.org/subfields/1305
topics[1].subfield.display_name	Biotechnology
topics[1].display_name	Transgenic Plants and Applications
topics[2].id	https://openalex.org/T10837
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9902999997138977
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2708
topics[2].subfield.display_name	Dermatology
topics[2].display_name	Dermatology and Skin Diseases
funders[0].id	https://openalex.org/F4320311405
funders[0].ror	https://ror.org/004rtk039
funders[0].display_name	Japan Agency for Medical Research and Development
funders[1].id	https://openalex.org/F4320334764
funders[1].ror	https://ror.org/00hhkn466
funders[1].display_name	Japan Society for the Promotion of Science
is_xpac	False
apc_list.value	2500
apc_list.currency	USD
apc_list.value_usd	2500
apc_paid.value	2500
apc_paid.currency	USD
apc_paid.value_usd	2500
concepts[0].id	https://openalex.org/C71924100
concepts[0].level	0
concepts[0].score	0.8859014511108398
concepts[0].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[0].display_name	Medicine
concepts[1].id	https://openalex.org/C2777756187
concepts[1].level	3
concepts[1].score	0.8473504185676575
concepts[1].wikidata	https://www.wikidata.org/wiki/Q1891209
concepts[1].display_name	Mycosis fungoides
concepts[2].id	https://openalex.org/C2778329239
concepts[2].level	2
concepts[2].score	0.7887524366378784
concepts[2].wikidata	https://www.wikidata.org/wiki/Q268667
concepts[2].display_name	Atopic dermatitis
concepts[3].id	https://openalex.org/C16005928
concepts[3].level	1
concepts[3].score	0.619223952293396
concepts[3].wikidata	https://www.wikidata.org/wiki/Q171171
concepts[3].display_name	Dermatology
concepts[4].id	https://openalex.org/C203014093
concepts[4].level	1
concepts[4].score	0.3952251374721527
concepts[4].wikidata	https://www.wikidata.org/wiki/Q101929
concepts[4].display_name	Immunology
concepts[5].id	https://openalex.org/C2779338263
concepts[5].level	2
concepts[5].score	0.1307956874370575
concepts[5].wikidata	https://www.wikidata.org/wiki/Q208414
concepts[5].display_name	Lymphoma
keywords[0].id	https://openalex.org/keywords/medicine
keywords[0].score	0.8859014511108398
keywords[0].display_name	Medicine
keywords[1].id	https://openalex.org/keywords/mycosis-fungoides
keywords[1].score	0.8473504185676575
keywords[1].display_name	Mycosis fungoides
keywords[2].id	https://openalex.org/keywords/atopic-dermatitis
keywords[2].score	0.7887524366378784
keywords[2].display_name	Atopic dermatitis
keywords[3].id	https://openalex.org/keywords/dermatology
keywords[3].score	0.619223952293396
keywords[3].display_name	Dermatology
keywords[4].id	https://openalex.org/keywords/immunology
keywords[4].score	0.3952251374721527
keywords[4].display_name	Immunology
keywords[5].id	https://openalex.org/keywords/lymphoma
keywords[5].score	0.1307956874370575
keywords[5].display_name	Lymphoma
language	en
locations[0].id	doi:10.1155/dth/6603966
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S67424211
locations[0].source.issn	1396-0296, 1529-8019
locations[0].source.type	journal
locations[0].source.is_oa	False
locations[0].source.issn_l	1396-0296
locations[0].source.is_core	True
locations[0].source.is_in_doaj	False
locations[0].source.display_name	Dermatologic Therapy
locations[0].source.host_organization	https://openalex.org/P4310320595
locations[0].source.host_organization_name	Wiley
locations[0].source.host_organization_lineage	https://openalex.org/P4310320595
locations[0].source.host_organization_lineage_names	Wiley
locations[0].license	cc-by
locations[0].pdf_url	https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/dth/6603966
locations[0].version	publishedVersion
locations[0].raw_type	journal-article
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	True
locations[0].raw_source_name	Dermatologic Therapy
locations[0].landing_page_url	https://doi.org/10.1155/dth/6603966
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5000312765
authorships[0].author.orcid	https://orcid.org/0000-0003-0829-8780
authorships[0].author.display_name	Manami Takahashi
authorships[0].author_position	first
authorships[0].raw_author_name	Manami Takahashi-Watanabe
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5031821817
authorships[1].author.orcid	https://orcid.org/0000-0001-6809-5833
authorships[1].author.display_name	Taku Fujimura
authorships[1].author_position	middle
authorships[1].raw_author_name	Taku Fujimura
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5080183656
authorships[2].author.orcid	https://orcid.org/0000-0002-1189-3962
authorships[2].author.display_name	Emi Yamazaki
authorships[2].author_position	middle
authorships[2].raw_author_name	Emi Yamazaki
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5014048733
authorships[3].author.orcid	https://orcid.org/0009-0008-3337-5657
authorships[3].author.display_name	Ryo Amagai
authorships[3].author_position	middle
authorships[3].raw_author_name	Ryo Amagai
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5040499392
authorships[4].author.orcid	https://orcid.org/0000-0002-6412-9570
authorships[4].author.display_name	Kenta Oka
authorships[4].author_position	middle
authorships[4].raw_author_name	Kenta Oka
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5039882708
authorships[5].author.orcid	https://orcid.org/0000-0003-3866-5609
authorships[5].author.display_name	Yumi Kambayashi
authorships[5].author_position	middle
authorships[5].raw_author_name	Yumi Kambayashi
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5061963334
authorships[6].author.orcid	https://orcid.org/0000-0002-6927-3125
authorships[6].author.display_name	Maki Ozawa
authorships[6].author_position	middle
authorships[6].raw_author_name	Maki Ozawa
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5109251215
authorships[7].author.orcid
authorships[7].author.display_name	Tomoko Chiba
authorships[7].author_position	middle
authorships[7].raw_author_name	Tomoko Chiba
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5081181566
authorships[8].author.orcid	https://orcid.org/0000-0002-8243-8537
authorships[8].author.display_name	Mayuko Onodera-Amagai
authorships[8].author_position	middle
authorships[8].raw_author_name	Mayuko Onodera-Amagai
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5031099621
authorships[9].author.orcid	https://orcid.org/0000-0001-9742-2282
authorships[9].author.display_name	Toshiya Takahashi
authorships[9].author_position	middle
authorships[9].raw_author_name	Toshiya Takahashi
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5007508591
authorships[10].author.orcid	https://orcid.org/0000-0001-5560-9778
authorships[10].author.display_name	Yoshihide Asano
authorships[10].author_position	last
authorships[10].raw_author_name	Yoshihide Asano
authorships[10].is_corresponding	False
has_content.pdf	True
has_content.grobid_xml	True
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/dth/6603966
open_access.oa_status	hybrid
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Comprehensive Analysis of the Chemokine/Cytokine Profiles in Advanced Mycosis Fungoides and Atopic Dermatitis
has_fulltext	True
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T11811
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9976000189781189
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2708
primary_topic.subfield.display_name	Dermatology
primary_topic.display_name	Cutaneous lymphoproliferative disorders research
related_works	https://openalex.org/W2899084033, https://openalex.org/W2748952813, https://openalex.org/W3031052312, https://openalex.org/W4389568370, https://openalex.org/W3032375762, https://openalex.org/W1995515455, https://openalex.org/W2080531066, https://openalex.org/W3108674512, https://openalex.org/W1600738891, https://openalex.org/W3024829390
cited_by_count	1
counts_by_year[0].year	2025
counts_by_year[0].cited_by_count	1
locations_count	1
best_oa_location.id	doi:10.1155/dth/6603966
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S67424211
best_oa_location.source.issn	1396-0296, 1529-8019
best_oa_location.source.type	journal
best_oa_location.source.is_oa	False
best_oa_location.source.issn_l	1396-0296
best_oa_location.source.is_core	True
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	Dermatologic Therapy
best_oa_location.source.host_organization	https://openalex.org/P4310320595
best_oa_location.source.host_organization_name	Wiley
best_oa_location.source.host_organization_lineage	https://openalex.org/P4310320595
best_oa_location.source.host_organization_lineage_names	Wiley
best_oa_location.license	cc-by
best_oa_location.pdf_url	https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/dth/6603966
best_oa_location.version	publishedVersion
best_oa_location.raw_type	journal-article
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	True
best_oa_location.raw_source_name	Dermatologic Therapy
best_oa_location.landing_page_url	https://doi.org/10.1155/dth/6603966
primary_location.id	doi:10.1155/dth/6603966
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S67424211
primary_location.source.issn	1396-0296, 1529-8019
primary_location.source.type	journal
primary_location.source.is_oa	False
primary_location.source.issn_l	1396-0296
primary_location.source.is_core	True
primary_location.source.is_in_doaj	False
primary_location.source.display_name	Dermatologic Therapy
primary_location.source.host_organization	https://openalex.org/P4310320595
primary_location.source.host_organization_name	Wiley
primary_location.source.host_organization_lineage	https://openalex.org/P4310320595
primary_location.source.host_organization_lineage_names	Wiley
primary_location.license	cc-by
primary_location.pdf_url	https://onlinelibrary.wiley.com/doi/pdfdirect/10.1155/dth/6603966
primary_location.version	publishedVersion
primary_location.raw_type	journal-article
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	True
primary_location.raw_source_name	Dermatologic Therapy
primary_location.landing_page_url	https://doi.org/10.1155/dth/6603966
publication_date	2025-01-01
publication_year	2025
referenced_works	https://openalex.org/W3022297803, https://openalex.org/W3100066710, https://openalex.org/W4394008790, https://openalex.org/W4389285796, https://openalex.org/W4396510195, https://openalex.org/W1881313444, https://openalex.org/W3049896770, https://openalex.org/W2058500927, https://openalex.org/W4391144751, https://openalex.org/W4297965106, https://openalex.org/W64785542, https://openalex.org/W2474733682, https://openalex.org/W4399180668, https://openalex.org/W2290954029, https://openalex.org/W4390632383, https://openalex.org/W4306686709, https://openalex.org/W4313827491, https://openalex.org/W2104802268, https://openalex.org/W3194107711, https://openalex.org/W2136267701, https://openalex.org/W2060857853, https://openalex.org/W1972725501, https://openalex.org/W2012340615, https://openalex.org/W4214864099, https://openalex.org/W2971706488
referenced_works_count	25
abstract_inverted_index.=	102, 112
abstract_inverted_index.11	89
abstract_inverted_index.16	94, 104
abstract_inverted_index.21	115
abstract_inverted_index.40	123
abstract_inverted_index.AD	98, 108, 146, 164, 211
abstract_inverted_index.In	150, 215
abstract_inverted_index.MF	61, 140, 168, 191, 238
abstract_inverted_index.We	29
abstract_inverted_index.an	4, 183
abstract_inverted_index.be	17, 230
abstract_inverted_index.by	62
abstract_inverted_index.in	38, 52, 132, 139, 162, 204, 209, 221, 232
abstract_inverted_index.is	3
abstract_inverted_index.of	7, 24, 41, 60, 78, 85, 91, 96, 106, 224, 236
abstract_inverted_index.on	64
abstract_inverted_index.to	16, 47, 70, 81, 143, 167, 182, 213, 217, 245
abstract_inverted_index.we	45
abstract_inverted_index.AD.	193, 240
abstract_inverted_index.Its	11
abstract_inverted_index.MF,	93
abstract_inverted_index.MF.	43, 86, 214
abstract_inverted_index.Our	173
abstract_inverted_index.The	127
abstract_inverted_index.and	67, 69, 114, 147, 157, 170, 179, 197, 239
abstract_inverted_index.are	14, 36, 201, 207, 243
abstract_inverted_index.for	74, 187
abstract_inverted_index.may	229
abstract_inverted_index.the	39, 50, 53, 57, 75, 79, 82, 121, 219, 222, 233
abstract_inverted_index.(AD)	22
abstract_inverted_index.(MF)	2
abstract_inverted_index.EASI	100, 110
abstract_inverted_index.MIF,	137
abstract_inverted_index.Sera	87
abstract_inverted_index.form	6
abstract_inverted_index.from	19, 88, 192
abstract_inverted_index.have	30
abstract_inverted_index.mild	97
abstract_inverted_index.that	33, 176
abstract_inverted_index.were	118, 159
abstract_inverted_index.with	145
abstract_inverted_index.CCL1,	153
abstract_inverted_index.CCL26	158
abstract_inverted_index.CCL3)	138
abstract_inverted_index.CCL7,	154
abstract_inverted_index.cases	90, 95, 105
abstract_inverted_index.early	12, 76, 237
abstract_inverted_index.phase	59, 84
abstract_inverted_index.score	101, 111
abstract_inverted_index.serum	65
abstract_inverted_index.their	25
abstract_inverted_index.these	225, 227, 247
abstract_inverted_index.those	144
abstract_inverted_index.tumor	188
abstract_inverted_index.using	120
abstract_inverted_index.which	200
abstract_inverted_index.28.1),	113
abstract_inverted_index.5.75),	103
abstract_inverted_index.CCL21,	155
abstract_inverted_index.CCL25,	156
abstract_inverted_index.atopic	20
abstract_inverted_index.during	56
abstract_inverted_index.immune	27, 54
abstract_inverted_index.mainly	202
abstract_inverted_index.severe	107, 163, 210
abstract_inverted_index.sought	46
abstract_inverted_index.(median	99, 109
abstract_inverted_index.Further	241
abstract_inverted_index.IL‐2,	152
abstract_inverted_index.Mycosis	0
abstract_inverted_index.analyze	49
abstract_inverted_index.because	23
abstract_inverted_index.changes	51
abstract_inverted_index.confirm	246
abstract_inverted_index.factors	135, 228
abstract_inverted_index.growth,	189
abstract_inverted_index.healthy	116, 148, 171
abstract_inverted_index.lesions	13
abstract_inverted_index.results	128
abstract_inverted_index.several	34, 177
abstract_inverted_index.similar	26
abstract_inverted_index.studies	242
abstract_inverted_index.suggest	175
abstract_inverted_index.system.	126
abstract_inverted_index.(IL‐4,	136
abstract_inverted_index.T‐cell	9, 195
abstract_inverted_index.addition	216
abstract_inverted_index.advanced	42, 58, 83
abstract_inverted_index.analyzed	119
abstract_inverted_index.compared	142, 166, 212
abstract_inverted_index.elevated	208
abstract_inverted_index.factors,	199
abstract_inverted_index.findings	174
abstract_inverted_index.focusing	63
abstract_inverted_index.identify	71
abstract_inverted_index.indolent	5
abstract_inverted_index.involved	37, 203
abstract_inverted_index.patients	141, 165, 169
abstract_inverted_index.revealed	129
abstract_inverted_index.Moreover,	194
abstract_inverted_index.contrast,	151
abstract_inverted_index.controls.	149, 172
abstract_inverted_index.cutaneous	8
abstract_inverted_index.cytokines	66, 180
abstract_inverted_index.detection	77
abstract_inverted_index.diagnosis	235
abstract_inverted_index.diseases,	226
abstract_inverted_index.favorable	186
abstract_inverted_index.findings.	248
abstract_inverted_index.fungoides	1
abstract_inverted_index.important	15, 231
abstract_inverted_index.increased	161
abstract_inverted_index.increases	131
abstract_inverted_index.lymphoma.	10
abstract_inverted_index.migration	198
abstract_inverted_index.multiplex	124
abstract_inverted_index.potential	72
abstract_inverted_index.warranted	244
abstract_inverted_index.Bio‐Plex	122
abstract_inverted_index.Therefore,	44
abstract_inverted_index.biomarkers	73
abstract_inverted_index.chemokines	35, 68, 178
abstract_inverted_index.contribute	181
abstract_inverted_index.dermatitis	21
abstract_inverted_index.previously	31
abstract_inverted_index.transition	80
abstract_inverted_index.volunteers	117
abstract_inverted_index.differences	220
abstract_inverted_index.elucidating	218
abstract_inverted_index.environment	55, 185
abstract_inverted_index.immunoassay	125
abstract_inverted_index.maintaining	205
abstract_inverted_index.significant	130
abstract_inverted_index.demonstrated	32
abstract_inverted_index.differential	234
abstract_inverted_index.pathogenesis	40, 223
abstract_inverted_index.distinguished	18
abstract_inverted_index.inflammation,	206
abstract_inverted_index.proliferation	196
abstract_inverted_index.significantly	160
abstract_inverted_index.distinguishing	190
abstract_inverted_index.comprehensively	48
abstract_inverted_index.advanced‐stage	92
abstract_inverted_index.immunosuppressive	133, 184
abstract_inverted_index.microenvironment.	28
abstract_inverted_index.macrophage‐related	134
cited_by_percentile_year.max	95
cited_by_percentile_year.min	91
countries_distinct_count	0
institutions_distinct_count	11
citation_normalized_percentile.value	0.89746243
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	True